Veterans Affairs Medical Center - Little Rock (McClellan)

Summary

Veterans Affairs Medical Center - Little Rock (McClellan) is a medical facility located in Little Rock, Arkansas. This center is recognized for care of Lung Cancer, Leukemia, Lymphoma, Melanoma, Bladder Cancer and other specialties. Veterans Affairs Medical Center - Little Rock (McClellan) is involved with conducting 111 clinical trials across 144 conditions. There are 7 research doctors associated with this hospital, such as Rangaswamy Govindarajan, Barry Uretsky, MD, Mohammed Moursi, MD, and Alison Acott, MD.

Top PIs

Clinical Trials running at Veterans Affairs Medical Center - Little Rock (McClellan)

Multiple Myeloma

Coronary Artery Disease

Atherosclerosis

Heart Failure

Peripheral Artery Disease

Cerebrovascular Disease

Incretin Hormones in Polycystic Ovary Syndrome

Prediabetes

Metformin

Liver Dysfunction

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria

Drug Combinations

for Multiple Myeloma

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.

Recruiting

2 awards

Phase 3

21 criteria